BioAlliance Pharma SA (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
BioAlliance Pharma SA (BioAlliance) is a biopharmaceutical company. The company focuses on developing drugs for the treatment of cancer and its related pathologies. The company offers products in two product catagories namely orphan oncology and speciality. Products. Its product pipeline under orphan oncology category include Livatag, in phase 3 of clinical trials, Validive, in phase 2 of clinical trials, AMEP in phase 1 of clinical trials, and Irinotecan Transdrug in preclinical stage of trials.
BioAlliance Pharma SA Key Recent Developments
Apr 30, 2014: BioAlliance Pharma Release: Quarterly Information As Of March 31, 2014
Feb 27, 2014: BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results
Nov 14, 2013: BioAlliance Pharma : Quarterly information as of September 30, 2013
Oct 22, 2013: BioAlliance Pharma launches its new website
Sep 19, 2013: BioAlliance Pharma: Key milestones and consolidated accounts
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
BioAlliance Pharma SA - Key Facts 6
BioAlliance Pharma SA - Key Employees 7
BioAlliance Pharma SA - Key Employee Biographies 8
BioAlliance Pharma SA - Major Products and Services 9
BioAlliance Pharma SA - Pharmaceutical Pipeline Products Data 10
BioAlliance Pharma SA, Pipeline Products by Therapy Area 10
BioAlliance Pharma SA, Pipeline Products by Development Phase 11
BioAlliance Pharma SA - History 13
BioAlliance Pharma SA - Company Statement 17
BioAlliance Pharma SA - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Joint Venture 18
Section 2 – Company Analysis 19
BioAlliance Pharma SA - Business Description 19
BioAlliance Pharma SA - Corporate Strategy 20
BioAlliance Pharma SA - SWOT Analysis 21
SWOT Analysis - Overview 21
BioAlliance Pharma SA - Strengths 21
Strength - Focus on Orphan diseases 21
Strength - Proprietary Technologies 21
Strength - License Agreements 21
BioAlliance Pharma SA - Weaknesses 22
Weakness - Weak Financial Performance 22
BioAlliance Pharma SA - Opportunities 22
Opportunity - Strategic Initiatives 22
Opportunity - Pipeline Products 22
Opportunity - Market Potential: Cancer 22
BioAlliance Pharma SA - Threats 23
Threat - Growing Parallel Trade 23
Threat - Industry Consolidation 23
Threat - Uncertain R&D Outcomes 23
BioAlliance Pharma SA - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
BioAlliance Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 30
BioAlliance Pharma SA, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 31
BioAlliance Pharma SA, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Apr 30, 2014: BioAlliance Pharma Release: Quarterly Information As Of March 31, 2014 33
Feb 27, 2014: BioAlliance Pharma Provides Updates on Its Major Achievements and Reports 2013 Consolidated Financial Results 33
Nov 14, 2013: BioAlliance Pharma : Quarterly information as of September 30, 2013 34
Oct 22, 2013: BioAlliance Pharma launches its new website 35
Sep 19, 2013: BioAlliance Pharma: Key milestones and consolidated accounts 35
Jun 27, 2013: BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Russell Greig and Danièle Guyot-Caparros As Independant Board Members 36
Jun 27, 2013: BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Russell Greig and Danièle Guyot-Caparros As Independant Board Members 37
Apr 15, 2013: BioAlliance Pharma Reports Q1 2013 Results 38
Apr 15, 2013: BioAlliance Pharma Reports Revenue Of €4m In 2012 38
Section 6 – Appendix 39
Methodology 39
Ratio Definitions 39
About GlobalData 43
Contact Us 43
Disclaimer 43
List Of Tables
List of Tables
BioAlliance Pharma SA, Key Facts 6
BioAlliance Pharma SA, Key Employees 7
BioAlliance Pharma SA, Key Employee Biographies 8
BioAlliance Pharma SA, Major Products and Services 9
BioAlliance Pharma SA, Number of Pipeline Products by Therapy Area 10
BioAlliance Pharma SA, Number of Pipeline Products by Development Stage 11
BioAlliance Pharma SA, Pipeline Products By Therapy Area and Development Phase 12
BioAlliance Pharma SA, History 13
BioAlliance Pharma SA, Subsidiaries 18
BioAlliance Pharma SA, Joint Venture 18
BioAlliance Pharma SA, Key Competitors 24
BioAlliance Pharma SA, Ratios based on current share price 25
BioAlliance Pharma SA, Annual Ratios 26
BioAlliance Pharma SA, Interim Ratios 28
BioAlliance Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 30
BioAlliance Pharma SA, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 31
BioAlliance Pharma SA, Recent Deals Summary 32
Currency Codes 39
Capital Market Ratios 39
Equity Ratios 40
Profitability Ratios 40
Cost Ratios 41
Liquidity Ratios 41
Leverage Ratios 42
Efficiency Ratios 42
List Of Figures
List of Figures
BioAlliance Pharma SA, Pipeline Products by Therapy Area 10
BioAlliance Pharma SA, Pipeline Products by Development Phase 11
BioAlliance Pharma SA, Performance Chart (2008 - 2012) 27
BioAlliance Pharma SA, Ratio Charts 29
BioAlliance Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 30
BioAlliance Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 31
